(Q50309492)

2 March 2018

title

Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report (English)

1 reference

2 March 2018

0 references

1

Monique P Curran

1 reference

2 March 2018

publication date

1 September 2011

1 reference

2 March 2018

published in

CNS Drugs

1 reference

2 March 2018

volume

25

1 reference

2 March 2018

issue

9

1 reference

2 March 2018

page(s)

801-802

1 reference

2 March 2018

Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11208280-000000000-00000

An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208280-000000000-00000

The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208280-000000000-00000

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208280-000000000-00000

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208280-000000000-00000

Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21870890

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2165/11208280-000000000-00000

1 reference

2 March 2018

Dimensions Publication ID

1014521853

0 references

1 reference

2 March 2018